US Stock MarketDetailed Quotes
NVCT Nuvectis Pharma
- 7.030
- +0.860+13.94%
Close Aug 5 16:00 ET
- 7.100
- +0.070+1.00%
Post 18:59 ET
129.04MMarket Cap-4985P/E (TTM)
7.190High5.850Low107.80KVolume5.870Open6.170Pre Close709.78KTurnover1.70%Turnover RatioLossP/E (Static)18.36MShares15.50052wk High9.20P/B44.63MFloat Cap5.85052wk Low--Dividend TTM6.35MShs Float20.920Historical High--Div YieldTTM21.72%Amplitude3.080Historical Low6.584Avg Price1Lot Size
Nuvectis Pharma Key Stats
Quarterly+Annual
YOY
| (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating revenue | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 |
| Cost of revenue | ||||||||||
| Gross profit | ||||||||||
| Operating expense | 7.19%4.4M | 19.04%22.9M | 1.30%6.87M | 3.70%6.16M | 61.54%5.77M | 39.25%4.1M | 49.17%19.23M | 199.25%6.78M | 27.21%5.94M | -39.83%3.57M |
| Selling and administrative expenses | 0.12%1.74M | 25.14%7.52M | 9.24%2.6M | 17.91%1.67M | 41.39%1.51M | 52.11%1.73M | 79.37%6.01M | 112.40%2.38M | 176.95%1.42M | -36.92%1.07M |
| -General and administrative expense | 0.12%1.74M | 25.14%7.52M | 9.24%2.6M | 17.91%1.67M | 41.39%1.51M | 52.11%1.73M | 79.37%6.01M | 112.40%2.38M | 176.95%1.42M | -36.92%1.07M |
| Research and development costs | 12.38%2.66M | 16.28%15.38M | -3.00%4.27M | -0.75%4.49M | 70.14%4.26M | 31.14%2.37M | 38.58%13.23M | 284.35%4.4M | 8.76%4.52M | -40.99%2.51M |
| Operating profit | -7.19%-4.4M | -19.04%-22.9M | -1.30%-6.87M | -3.70%-6.16M | -61.54%-5.77M | -39.25%-4.1M | -49.17%-19.23M | -199.25%-6.78M | -27.21%-5.94M | 39.83%-3.57M |
| Net non-operating interest income expense | 332.69%225K | 327.52%637K | 197.56%244K | 354.10%277K | 1,500.00%64K | 2,500.00%52K | 3,625.00%149K | 1,950.00%82K | 61K | 4K |
| Non-operating interest income | 332.69%225K | 327.52%637K | 197.56%244K | 354.10%277K | 1,500.00%64K | 2,500.00%52K | 3,625.00%149K | 1,950.00%82K | --61K | --4K |
| Other net income (expense) | ||||||||||
| Income before tax | -3.01%-4.17M | -16.64%-22.26M | 1.11%-6.62M | -0.07%-5.88M | -59.93%-5.71M | -37.58%-4.05M | -48.06%-19.09M | -196.15%-6.7M | -25.90%-5.88M | 39.90%-3.57M |
| Income tax | ||||||||||
| Net income | -3.01%-4.17M | -16.64%-22.26M | 1.11%-6.62M | -0.07%-5.88M | -59.93%-5.71M | -37.58%-4.05M | -48.06%-19.09M | -196.15%-6.7M | -25.90%-5.88M | 39.90%-3.57M |
| Net income continuous Operations | -3.01%-4.17M | -16.64%-22.26M | 1.11%-6.62M | -0.07%-5.88M | -59.93%-5.71M | -37.58%-4.05M | -48.06%-19.09M | -196.15%-6.7M | -25.90%-5.88M | 39.90%-3.57M |
| Minority interest income | ||||||||||
| Net income attributable to the parent company | -3.01%-4.17M | -16.64%-22.26M | 1.11%-6.62M | -0.07%-5.88M | -59.93%-5.71M | -37.58%-4.05M | -48.06%-19.09M | -196.15%-6.7M | -25.90%-5.88M | 39.90%-3.57M |
| Preferred stock dividends | ||||||||||
| Other preferred stock dividends | ||||||||||
| Net income attributable to common stockholders | -3.01%-4.17M | -16.64%-22.26M | 1.11%-6.62M | -0.07%-5.88M | -59.93%-5.71M | -37.58%-4.05M | -48.06%-19.09M | -196.15%-6.7M | -25.90%-5.88M | 39.90%-3.57M |
| Basic earnings per share | 7.41%-0.25 | 5.30%-1.43 | 14.58%-0.41 | 11.90%-0.37 | -35.71%-0.38 | 15.63%-0.27 | -38.44%-1.51 | -150.89%-0.48 | -6.33%-0.42 | 40.03%-0.28 |
| Diluted earnings per share | 7.41%-0.25 | 5.30%-1.43 | 14.58%-0.41 | 11.90%-0.37 | -35.71%-0.38 | 15.63%-0.27 | -38.44%-1.51 | -150.89%-0.48 | -6.33%-0.42 | 40.03%-0.28 |
| Dividend per share | ||||||||||
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg